Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effects of VV913 in Healthy Volunteers
NCT07565792Phase 1Recruiting
- Sponsor
- Vigonvita Life Sciences
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VV913 (3 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Incidence of Adverse Events, Maximum Observed Plasma Concentration at 72 hours and 2 more. Started May 2026; status: recruiting.
02
Drugs
VV913
Beyond the preview
Go deeper on NCT07565792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565792.